halaven

lenvima

HALAVEN® (eribulin mesylate) Injection – for intravenous administration only.

Indication Halaven® is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

For more information, please contact NewBridge on [email protected]

lenvima